Iqvia (NYSE: IQV) and Rosetta Genomics (NASDAQ:ROSG) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.
This table compares Iqvia and Rosetta Genomics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of recent ratings and target prices for Iqvia and Rosetta Genomics, as provided by MarketBeat.
||Strong Buy Ratings
Iqvia presently has a consensus target price of $109.56, indicating a potential upside of 4.66%. Given Iqvia’s stronger consensus rating and higher probable upside, equities analysts plainly believe Iqvia is more favorable than Rosetta Genomics.
Earnings and Valuation
This table compares Iqvia and Rosetta Genomics’ gross revenue, earnings per share and valuation.
||Earnings Per Share
Iqvia has higher revenue and earnings than Rosetta Genomics.
Risk and Volatility
Iqvia has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.
Insider and Institutional Ownership
95.9% of Iqvia shares are held by institutional investors. Comparatively, 7.5% of Rosetta Genomics shares are held by institutional investors. 6.4% of Iqvia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Iqvia beats Rosetta Genomics on 12 of the 12 factors compared between the two stocks.
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.